SCHEMBL13282911

SCHEMBL13282911

CSc1nc2cccc(F)c2c(=O)n1NC(=O)Cc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.44
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
CACNA1G O43497 2/20 0.40
CACNA1H O95180 2/20 0.40
CACNA1I Q9P0X4 2/20 0.40
P2RY14 Q15391 2/20 0.40
NLRP3 Q96P20 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.39
ENPP2 Q13822 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
LTA4H P09960 1/20 0.38
EPHX2 P34913 1/20 0.38
CSNK1D P48730 1/20 0.38
GPR139 Q6DWJ6 4/20 0.38
WNT3A P56704 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378668 0.88 NPSR1 (0.45) ALDH1A1LMNANPSR1HTTRAB9A
SCHEMBL13282987 0.86 ALDH1A1 (0.57) ALDH1A1LMNACACNA1GCACNA1HCACNA1I
SCHEMBL13102403 0.84 TRPV4 (0.43) TRPV4ALDH1A1LMNACACNA1GCACNA1H
SCHEMBL13282996 0.82 HTT (0.44) ALDH1A1LMNANPSR1HTTRAB9A
SCHEMBL13283034 0.79 NPSR1 (0.48) ALDH1A1LMNANPSR1HTTRAB9A
SCHEMBL13283153 0.79 NPSR1 (0.52) ALDH1A1LMNACACNA1GCACNA1HCACNA1I
SCHEMBL13282920 0.78 NPSR1 (0.53) ALDH1A1LMNAP2RY14NPSR1HTT
SCHEMBL13282879 0.78 ALDH1A1 (0.44) ALDH1A1LMNANPSR1HTTRAB9A
SCHEMBL13283005 0.77 RAB9A (0.45) ALDH1A1LMNANPSR1HTTRAB9A
SCHEMBL13282994 0.77 NPSR1 (0.59) ALDH1A1LMNACACNA1GCACNA1HCACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS KCNQ1, KCNK17, KCNQ2 TRPV4 175/4885ALDH1A1 2776/4885LMNA 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.